Technical Analysis for RUBY - Rubius Therapeutics, Inc.

Grade Last Price % Change Price Change
grade D 16.53 4.16% 0.66
RUBY closed up 4.16 percent on Wednesday, April 24, 2019, on 57 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong N/A Down Down
See historical RUBY trend table...

Date Alert Name Type % Chg
MACD Bearish Centerline Cross Bearish 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Lower Bollinger Band Walk Weakness 4.16%
Inside Day Range Contraction 4.16%
Below Lower BB Weakness 4.16%
Down 3 Days in a Row Weakness 4.16%
Down 4 Days in a Row Weakness 4.16%
Lower Bollinger Band Touch Weakness 4.16%

Older signals for RUBY ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Rubius Therapeutics Inc is a biotechnology company that develops cellular therapies for cancer, and enzyme deficiency diseases. The Company develops Red-Cell Therapeutics (RCT) products using red platform. RCT is a red blood cell-based therapy for applications in cancer, enzyme replacement therapies, and autoimmune disease and tolerance induction. Its RCT product candidate is designed to provide various attributes, which include broad therapeutic applications, predictable bio-distribution and advantageous tolerability. It is initially focused on advancing RCT product candidates for patients suffering from rare diseases, cancer and autoimmune diseases based on three modalities - cellular shielding, potent cell-cell interaction and tolerance induction. Its product candidates in rare diseases include RTX-134 for the treatment of phenylketonuria (PKU), RTX-134 followed by RTX-Uricase and RTX-CBS for the treatment of chronic refractory gout symptomatic homocystinuria.
Biotechnology Cancer Immunology Autoimmune Diseases Rare Diseases Application Software Autoimmunity Therapies For Cancer Autoimmune Disease Computer Aided Engineering Phenylketonuria Enzyme Replacement Therapies Therapeutic Applications
Is RUBY a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 33.01
52 Week Low 12.7
Average Volume 362,499
200-Day Moving Average 0.0
50-Day Moving Average 16.6674
20-Day Moving Average 18.3045
10-Day Moving Average 17.58
Average True Range 1.2483
ADX 25.33
+DI 14.5828
-DI 24.6539
Chandelier Exit (Long, 3 ATRs ) 16.2951
Chandelier Exit (Short, 3 ATRs ) 19.1349
Upper Bollinger Band 20.6717
Lower Bollinger Band 15.9373
Percent B (%b) 0.13
BandWidth 25.864678
MACD Line -0.0842
MACD Signal Line 0.3578
MACD Histogram -0.442
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 18.14
Resistance 3 (R3) 17.98 17.29 17.87
Resistance 2 (R2) 17.29 16.88 17.37 17.78
Resistance 1 (R1) 16.91 16.63 17.10 17.07 17.69
Pivot Point 16.22 16.22 16.32 16.30 16.22
Support 1 (S1) 15.84 15.81 16.03 16.00 15.37
Support 2 (S2) 15.15 15.56 15.23 15.28
Support 3 (S3) 14.77 15.15 15.19
Support 4 (S4) 14.93